Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
Norman Abbou, Geoffroy Venton(Inserm), Anne‐Laure Couderc(Centre National de la Recherche Scientifique), L’Houcine Ouafik(Centre National de la Recherche Scientifique), Robin Arcani(Inserm), Laure Farnault(Aix-Marseille Université), Régis Costello(Inserm), Pauline Piazzola(Hôpital de la Conception), Pierre‐Emmanuel Morange(Aix-Marseille Université), Julien Colle(Inserm), Jean Gabert(Hôpital Nord), Antoine Tichadou(Assistance Publique Hôpitaux de Marseille), Pauline Roché(Hôpital de la Conception), Vincent Ernest
Cited by 5
Related Papers
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
Meta-analysis of 65,734 Individuals Identifies TSPAN15 and SLC44A2 as Two Susceptibility Loci for Venous Thromboembolism
|The American Journal of Human Genetics|2015|274
Apolipoprotein(a) Genetic Sequence Variants Associated With Systemic Atherosclerosis and Coronary Atherosclerotic Burden But Not With Venous Thromboembolism
|Journal of the American College of Cardiology|2012|184